


Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		<b>Atty. Docket No. (Optional)</b>  15878		<b>Application Number</b>  10/533,595		
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>						
<i>(Use several sheets if necessary)</i>						
						
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA					
	AB					
	AC					
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>						
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA	2003/0068310 A1	4/10/03	Yin et al.		
	AB					
<b>FOREIGN PATENT DOCUMENTS</b>						
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	Moscat J. et al., "The Atypical Protein Kinase Cs", <i>EMBO Reports</i> , 1(5):399-403 (2000)					
	Shao C.Y. et al., "Atypical Protein Kinase C (PKC) Colocalizes with Tau and $\alpha$ -Synuclein-Related Inclusions in Neurodegenerative Disorders", <i>Society for Neuroscience Abstracts 02-07</i> (2002), Abstract 592.9					
	Shao C.Y. et al., "Association of PKC, P62 and Ubiquitin with Inclusions of Neurodegenerative Disease", <i>Society for Neuroscience Abstracts 08-12</i> (2003), Abstract 203.22					
	Hopf F.W. et al., "Atypical Protein Kinase C is a Novel Mediator of Dopamine-Enhanced Firing in Nucleus Accumbens Neurons", <i>The Journal of Neuroscience</i> , 25(4):985-989 (2005)					
EXAMINER			DATE CONSIDERED			
/Stacey Macfarlane/			04/04/2008			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

JC10 Rec'd PCT/PTO 20 JUN 2005

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 15878	
In Re Application Of: <b>Clodd C. Sacktor, et al.</b>					
Application No. 10/533,595	Filing Date May 2, 2005	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. Unassigned
Title: <b>ATYPICAL PROTEIN KINASE C ISOFORMS IN DISORDERS OF THE NERVOUS SYSTEM AND CANCER</b>					
<div style="text-align: center;"> <p>Address to:</p> <p><b>Commissioner for Patents</b></p> <p><b>P.O. Box 1450</b></p> <p><b>Alexandria, VA 22313-1450</b></p> </div> <p style="text-align: center;"><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;"><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px;"> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;"><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> </div>					

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Docket No.  
15878

Under 37 CFR 1.97(b) or 1.97(c)

In Re Application: Todd J. Sacktor, et al.

Application No. 10/533,595	Filing Date May 2, 2005	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. Unassigned
-------------------------------	----------------------------	------------------------	-----------------------	------------------------------	--------------------------------

Title:

ATYPICAL PROTEIN KINASE C ISOFORMS IN DISORDERS OF THE NERVOUS SYSTEM AND CANCER

## Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

## Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

## Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 16, 2005

(Date)

Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Signature

Dated: June 16, 2005

Peter I. Bernstein  
Registration No. 43,497  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
516-742-4343

CC: